|
1
|
Linehan WM, Srinivasan R and Schmidt LS:
The genetic basis of kidney cancer: A metabolic disease. Nat Rev
Urol. 7:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL
and Miller DC: Long-term survival following partial vs radical
nephrectomy among older patients with early-stage kidney cancer.
JAMA. 307:1629–1635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gohara A, Eltaki N, Sabry D, Murtagh D Jr,
Jankun J, Selman SH and Skrzypczak-Jankun E: Human 5-, 12- and
15-lipoxygenase-1 coexist in kidney but show opposite trends and
their balance changes in cancer. Oncol Rep. 28:1275–1282. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morrissey JJ, London AN, Luo J and
Kharasch ED: Urinary biomarkers for the early diagnosis of kidney
cancer. Mayo Clin Proc. 85:413–421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu SS, Quinn DI and Dorff TB: Clinical use
of cabozantinib in the treatment of advanced kidney cancer:
Efficacy, safety, and patient selection. OncoTargets Ther.
9:5825–5837. 2016. View Article : Google Scholar
|
|
6
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jonasch E: Incorporating New Systemic
Therapies in Kidney Cancer Treatment. J Natl Compr Canc Netw.
15(5S): 703–705. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dent P, Curiel DT and Fisher PB: The
potential of virus-based gene therapies for treatment of metastatic
kidney cancer. Expert Rev Anticancer Ther. 11:809–811. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Froger L, Neuzillet Y and Lebret T:
Indications for ablative treatment in kidney cancer in the elderly.
Prog Urol. 22:1004–1009. 2012.In French. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jaganjac S, Schefe L, Avdagić E, Spahović
H and Hiros M: Preoperative kidney tumor embolization as procedure
for therapy of advanced kidney cancer. Acta Inform Med. 22:302–305.
2014. View Article : Google Scholar
|
|
11
|
Kim YM, Kim EC and Kim Y: The human lysyl
oxidase-like 2 protein functions as an amine oxidase toward
collagen and elastin. Mol Biol Rep. 38:145–149. 2011. View Article : Google Scholar
|
|
12
|
Wu L and Zhu Y: The function and
mechanisms of action of LOXL2 in cancer (Review). Int J Mol Med.
36:1200–1204. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nishikawa R, Chiyomaru T, Enokida H,
Inoguchi S, Ishihara T, Matsushita R, Goto Y, Fukumoto I, Nakagawa
M and Seki N: Tumour-suppressive microRNA-29s directly regulate
LOXL2 expression and inhibit cancer cell migration and invasion in
renal cell carcinoma. FEBS Lett. 589:2136–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu D, Yao Q, Zhan C, Le-Meng Z, Liu H, Cai
Y, Tu C, Li X, Zou Y and Zhang S: MicroRNA-146a promote cell
migration and invasion in human colorectal cancer via
carboxypeptidase M/src-FAK pathway. Oncotarget. 8:22674–22684.
2017.PubMed/NCBI
|
|
15
|
Suwaki N, Vanhecke E, Atkins KM, Graf M,
Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, et al:
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a
therapeutic target in renal cell carcinoma. Sci Transl Med.
3:85ra472011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barker HE, Bird D, Lang G and Erler JT:
Tumor-secreted LOXL2 activates fibroblasts through FAK signaling.
Mol Cancer Res. 11:1425–1436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim BR, Dong SM, Seo SH, Lee JH, Lee JM,
Lee SH and Rho SB: Lysyl oxidase-like 2 (LOXL2) controls
tumor-associated cell proliferation through the interaction with
MARCKSL1. Cell Signal. 26:1765–1773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deckers IA, Schouten LJ, Van Neste L, van
Vlodrop IJ, Soetekouw PM, Baldewijns MM, Jeschke J, Ahuja N, Herman
JG, van den Brandt PA, et al: Promoter methylation of cdo1
identifies clear-cell renal cell cancer patients with poor survival
outcome. Clin Cancer Res. 21:3492–3500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brookman-May SD, May M, Wolff I, Zigeuner
R, Hutterer GC, Cindolo L, Schips L, De Cobelli O, Rocco B, De
Nunzio C, et al: CORONA Project; European Association of Urology
(EAU) Young Academic Urologists (YAU) Renal Cancer Group:
Evaluation of the prognostic significance of perirenal fat invasion
and tumor size in patients with pT1-pT3a localized renal cell
carcinoma in a comprehensive multicenter study of the CORONA
project. Can we improve prognostic discrimination for patients with
stage pT3a tumors? Eur Urol. 67:943–951. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kotsopoulos J, Zhang S, Akbari M, Salmena
L, Llacuachaqui M, Zeligs M, Sun P and Narod SA: BRCA1 mRNA levels
following a 4-6-week intervention with oral 3,3'-diindolylmethane.
Br J Cancer. 111:1269–1274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mickley A, Kovaleva O, Kzhyshkowska J and
Gratchev A: Molecular and immunologic markers of kidney
cancer-potential applications in predictive, preventive and
personalized medicine. EPMA J. 6:202015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi SE, Jeon N, Choi HY, Shin JI, Jeong
HJ and Lim BJ: Lysyl oxidase like 2 is expressed in kidney tissue
and is associated with the progression of tubulointerstitial
fibrosis. Mol Med Rep. 16:2477–2482. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hase H, Jingushi K, Ueda Y, Kitae K, Egawa
H, Ohshio I, Kawakami R, Kashiwagi Y, Tsukada Y, Kobayashi T, et
al: LOXL2 status correlates with tumor stage and regulates integrin
levels to promote tumor progression in ccRCC. Mol Cancer Res.
12:1807–1817. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Z, Xiaohua W, Lei J, Ruoyun T,
Mingxia X, Weichun H, Li F, Ping W and Junwei Y: Uric acid
increases fibronectin synthesis through upregulation of lysyl
oxidase expression in rat renal tubular epithelial cells. Am J
Physiol Renal Physiol. 299:F336–F346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fiore DC and Fox CL: Urology and
nephrology update: Bladder and kidney cancer. FP Essent. 416:26–29.
2014.PubMed/NCBI
|
|
26
|
Bianchi L, Rossi L, Tomao F, Papa A,
Zoratto F and Tomao S: Thyroid dysfunction and tyrosine kinase
inhibitors in renal cell carcinoma. Endocr Relat Cancer.
20:R233–R245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sakai M, Kato H, Sano A, Tanaka N, Inose
T, Kimura H, Sohda M, Nakajima M and Kuwano H: Expression of lysyl
oxidase is correlated with lymph node metastasis and poor prognosis
in esophageal squamous cell carcinoma. Ann Surg Oncol.
16:2494–2501. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Torres S, Garcia-Palmero I, Herrera M,
Bartolomé RA, Peña C, Fernandez-Aceñero MJ, Padilla G,
Peláez-García A, Lopez-Lucendo M, Rodriguez-Merlo R, et al: LOXL2
Is Highly Expressed in Cancer-Associated Fibroblasts and Associates
to Poor Colon Cancer Survival. Clin Cancer Res. 21:4892–4902. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chojnacka K and Mruk DD: The Src
non-receptor tyrosine kinase paradigm: New insights into mammalian
Sertoli cell biology. Mol Cell Endocrinol. 415:133–142. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pei G, Lan Y, Chen D, Ji L and Hua ZC: FAK
regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705
and PPARγ/miR-125b/Stat3 signaling pathway in B16F10 melanoma
cells. Oncotarget. 8:13898–13908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Majid S, Saini S, Dar AA, Hirata H,
Shahryari V, Tanaka Y, Yamamura S, Ueno K, Zaman MS, Singh K, et
al: MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal
cancer. Cancer Res. 71:2611–2621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Megison ML, Gillory LA, Stewart JE, Nabers
HC, Mrozcek-Musulman E and Beierle EA: FAK inhibition abrogates the
malignant phenotype in aggressive pediatric renal tumors. Mol
Cancer Res. 12:514–526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z,
Sun YM, Sun LC, Pan J, Sun LX, et al: Secreted LOXL2 is a novel
therapeutic target that promotes gastric cancer metastasis via the
Src/FAK pathway. Carcinogenesis. 30:1660–1669. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li RK, Zhao WY, Fang F, Zhuang C, Zhang
XX, Yang XM, Jiang SH, Kong FZ, Tu L, Zhang WM, et al: Lysyl
oxidase-like 4 (LOXL4) promotes proliferation and metastasis of
gastric cancer via FAK/Src pathway. J Cancer Res Clin Oncol.
141:269–281. 2015. View Article : Google Scholar
|
|
35
|
Baker AM, Cox TR, Bird D, Lang G, Murray
GI, Sun XF, Southall SM, Wilson JR and Erler JT: The role of lysyl
oxidase in SRC-dependent proliferation and metastasis of colorectal
cancer. J Natl Cancer Inst. 103:407–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baker AM, Bird D, Lang G, Cox TR and Erler
JT: Lysyl oxidase enzymatic function increases stiffness to drive
colorectal cancer progression through FAK. Oncogene. 32:1863–1868.
2013. View Article : Google Scholar
|
|
37
|
Raghu H, Sodadasu PK, Malla RR, Gondi CS,
Estes N and Rao JS: Localization of uPAR and MMP-9 in lipid rafts
is critical for migration, invasion and angiogenesis in human
breast cancer cells. BMC Cancer. 10:6472010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Asuthkar S, Nalla AK, Gondi CS, Dinh DH,
Gujrati M, Mohanam S and Rao JS: Gadd45a sensitizes medulloblastoma
cells to irradiation and suppresses MMP-9-mediated EMT.
Neuro-oncol. 13:1059–1073. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar
|
|
40
|
Zeng T, Peng L, Chao C, Fu B, Wang G, Wang
Y and Zhu X: miR-451 inhibits invasion and proliferation of bladder
cancer by regulating EMT. Int J Clin Exp Pathol. 7:7653–7662.
2014.
|
|
41
|
Myong NH: Loss of E-cadherin and
Acquisition of Vimentin in Epithelial-Mesenchymal Transition are
Noble Indicators of Uterine Cervix Cancer Progression. Korean J
Pathol. 46:341–348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Barker HE, Chang J, Cox TR, Lang G, Bird
D, Nicolau M, Evans HR, Gartland A and Erler JT: LOXL2-mediated
matrix remodeling in metastasis and mammary gland involution.
Cancer Res. 71:1561–1572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Park JS, Lee JH, Lee YS, Kim JK, Dong SM
and Yoon DS: Emerging role of LOXL2 in the promotion of pancreas
cancer metastasis. Oncotarget. 7:42539–42552. 2016.PubMed/NCBI
|
|
44
|
Baquero P, Jiménez-Mora E, Santos A, Lasa
M and Chiloeches A: TGFβ induces epithelial-mesenchymal transition
of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK
pathways. Mol Carcinog. 55:1639–1654. 2016. View Article : Google Scholar
|
|
45
|
Moon HJ, Finney J, Xu L, Moore D, Welch DR
and Mure M: MCF-7 cells expressing nuclear associated lysyl
oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal
transition (EMT) phenotype and are highly invasive in vitro. J Biol
Chem. 288:30000–30008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Park JE, Park B, Chae IG, Kim DH, Kundu J,
Kundu JK and Chun KS: [Corrigendum] Carnosic acid induces apoptosis
through inactivation of Src/STAT3 signaling pathway in human renal
carcinoma Caki cells. Oncol Rep. 36:37172016. View Article : Google Scholar
|
|
47
|
Tai G, Hohenstein P and Davies JA: FAK-Src
signalling is important to renal collecting duct morphogenesis:
Discovery using a hierarchical screening technique. Biol Open.
2:416–423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhan P, Shen XK, Qian Q, Zhu JP, Zhang Y,
Xie HY, Xu CH, Hao KK, Hu W, Xia N, et al: Down-regulation of lysyl
oxidase-like 2 (LOXL2) is associated with disease progression in
lung adenocarcinomas. Med Oncol. 29:648–655. 2012. View Article : Google Scholar
|
|
49
|
Kurozumi A, Kato M, Goto Y, Matsushita R,
Nishikawa R, Okato A, Fukumoto I, Ichikawa T and Seki N: Regulation
of the collagen cross-linking enzymes LOXL2 and PLOD2 by
tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J
Oncol. 48:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kasashima H, Yashiro M, Kinoshita H,
Fukuoka T, Morisaki T, Masuda G, Sakurai K, Kubo N, Ohira M and
Hirakawa K: Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts
stimulates the progression of gastric cancer. Cancer Lett.
354:438–446. 2014. View Article : Google Scholar : PubMed/NCBI
|
